Faberco Life Sciences Inc. (FLSI) played a pivotal role in the registration and Health Technology Assessment (HTA) approval of the Mylan HIV Self-test Kit, making this the first World Health Organization – Prequalified HIV-Self Test Kit approved in the Philippines. This milestone enables the HIV Self-test Kit inclusion in public procurement and distribution through Department of Health (DOH) and PhilHealth-supported programs, empowering key populations with accessible HIV screening options.
The HIV Self-Test Kit is a user-friendly, integrated blood-based device that delivers results in just 15 minutes, with 99.8% sensitivity and specificity, as validated by the World Health Organization (WHO). Link: PQDx_0320-090_00_Mylan_HIVSelfTest_v5.0.pdf
Designed for lay users, it allows individuals to screen for HIV-1 and HIV-2 antibodies privately and confidently in their own space, reducing barriers such as stigma, fear, and geographic inaccessibility. Each HIV self-test kit includes a Care Card designed to empower users with essential health information which provides contact details for support services, including the DOH’s National HIV/AIDS & STI Surveillance and Strategic Information Unit (NHSSS), and features a QR code that links to nearby prevention and care services.
Faberco’s efforts extend beyond regulatory milestones. The company initiatives are aligned with national health priorities, contributing to the HIV response through continuing medical education, stakeholder engagement, and capacity-building activities designed to complement government-led strategies reinforcing a shared commitment to reducing HIV cases in the Philippines.
The issuance of the Department of Health’s Administrative Order No. 2022-0035 “Guidelines in the Implementation of Differentiated HIV Testing Services” and the recent of HIV/AIDS Surveillance of the Philippines issued by Epidemiology Bureau, emphasized the urgency of expanding HIV testing, particularly considering rising infections among younger populations. This initiative supports proactive health decisions and strengthens the country’s commitment to ending HIV through accessible, stigma-free, and community-centered care.
Faberco Life Sciences Inc. remains committed to championing innovation and health equity. Its dedication to expanding access to HIV testing reflects a broader mission to support inclusive, sustainable, and impactful healthcare solutions for all Filipinos.